A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, Emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy
Ian D. Davis, Lynette Kiers, Lachlan MacGregor, Michael Quinn, Joseph Arezzo, Michael Green, Mark Rosenthal, Michael Chia, Michael Michael, Peter Bartley, Leonie Harrison, Michael Daly
Dive into the research topics of 'A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, Emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy'. Together they form a unique fingerprint.